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Abstract 
The functional significance of AKT in chronic lymphocytic leukemia (CLL) remains unclear. Given the 
importance of non-malignant T cells in regulating clonal expansion in CLL, we investigated the role of 
AKT in T cell-mediated cytoprotection and proliferation using an established co-culture system in 
which primary CLL cells were incubated on a monolayer of transfected mouse fibroblasts expressing 
human CD40L (CD154). Stimulation of CLL cells via CD40 induced activation of AKT, which was closely 
associated with downregulation of its negative regulator PTEN, and protected CLL cells from killing 
by bendamustine. This cytoprotective effect of CD40 stimulation was prevented by a selective 
inhibitor of AKT. Stimulation of CLL cells with CD154 + IL-4 or IL-21 induced proliferation detected as 
reduced fluorescence of cells pre-stained with CFSE. AKT inhibition produced a significant, consistent 
reduction in proliferation induced by CD154 + IL-4 and a reduction in proliferation induced by CD154 
+ IL-21 in most but not all cases. In contrast, AKT inhibition had no effect on the proliferation of 
normal B cells induced by CD154 + IL-4 or IL-21. These findings indicate that AKT contributes in a 
significant way to T-cell mediated survival and proliferation signalling in CLL and support the clinical 
evaluation of AKT inhibitors in this disease. 
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Introduction 
Chronic lymphocytic leukemia (CLL) is a malignancy of CD5+ B lymphocytes that accumulate in the 
blood, bone marrow and secondary lymphoid tissues such as lymph nodes. It is the most common 
form of leukemia in adults in the Western countries [1]. Despite recent therapeutic advances 
involving purine analogues and monoclonal antibodies [2], the disease remains incurable, and new 
therapeutic agents are therefore urgently required.  
Although the biology of CLL is still unclear [3,4], disease pathogenesis is most likely influenced by 
microenvironmental factors in affected tissues. It is now accepted that chronic stimulation of the B-
cell receptor (BCR) by antigen plays a key role in maintaining and expanding the malignant clone [5-
7]. However, the survival and proliferation of CLL cells are also thought to depend on their 
interactions with accessory cells [8,9]. One important interaction involves stimulation of CD40 on CLL 
cells by CD40 ligand (CD40L or CD154) on non-malignant T cells in affected lymph nodes [10,11]. 
Such cross-talk between CLL cells and accessory cells has been increasingly recognized to play an 
important role in disease progression, most likely through the activation of certain pro-survival or 
mitotic signalling pathways.  
One such pathway involves phosphatidylinositol 3-kinase (PI3K). The latter regulates a variety of 
important biological processes including cell growth, survival, migration, and metabolism [12,13]. 
Particularly relevant to CLL is the fact that PI3K can be activated by diverse stimuli that include 
antigens, cytokines and chemokines, as well as adhesion molecules [14,15]. Indeed, the aberrant 
activation of PI3K has been reported to contribute to the survival of CLL cells [16,17]. Thus targeting 
the PI3K pathway becomes an attractive strategy for development of novel therapeutic agents. In 
fact, the novel PI3K p110δ isoform-specific inhibitor, idelalisib, has significant clinical activity in CLL 
and is now approved for this indication [18-20]. Mechanistically, idelalisib has been shown to exhibit 
multiple modes of action – directly decreasing cell viability and disrupting interactions that retain 
CLL cells in protective tissue microenvironments [21,22], but also inducing egress of CLL cells from 
the lymph nodes [23]. 
The serine/threonine kinase AKT (also known as protein kinase B, PKB) is an important downstream 
effector of PI3K as it is largely responsible for PI3K-mediated pro-survival signalling [24,25]. AKT is 
also involved in regulation of other cellular processes including angiogenesis, metabolism, 
growth/proliferation, protein synthesis and transcription [24,26]. Dysregulation of AKT has thus 
been closely linked to the development of many human diseases including cancer [27,28].  
We and others have previously shown that AKT is critically involved in CLL cell-survival [29-32]. 
Pharmacological inhibition of AKT reduces the survival of CLL cells ex vivo under standard conditions 
[31,33], indicating that AKT inhibitors may have therapeutic potential in CLL. However, given that the 
survival and proliferation of CLL cells is closely regulated by the CLL microenvironment, it is 
important to understand the effect of AKT inhibition in CLL cells that are exposed to relevant stimuli. 
To this end, we co-cultured primary CLL cells on a stromal monolayer of transfected mouse 
fibroblasts expressing human CD154 to mimic the lymph node microenvironment and explored the 
distinct effects of AKT in mediating the survival, growth and proliferation of CLL cells induced by 
CD40 stimulation. 
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Results: 
1. Stimulation of CLL cells via CD40 induces AKT activation and reduced expression of PTEN 
irrespective of the presence of IL-4 or IL-21 
We have previously shown that CD40 stimulation (achieved by co-culturing CLL cells with CD154-
expressing fibroblasts) protected leukemic cells from killing by cytotoxic agents that induce 
apoptosis through activating the intrinsic mitochondrial or extrinsic death receptor-mediated 
pathway [34]. Although the cytoprotective effects of CD40 stimulation are known to be largely 
mediated by the transcription factor NF-κB [11], stimulating CLL cells with soluble CD40 ligand also 
resulted in activation of AKT, as measured by increased phosphorylation at serine 473 [21,35,36]. To 
establish whether AKT is also activated by membrane-bound CD40 ligand, levels of phospho-AKT (p-
AKT) were measured in primary CLL cells cultured on an adherent monolayer of CD154-expressing 
fibroblasts. As shown in Figure 1A, the level of p-AKT was consistently increased in CLL cells upon 
CD40 stimulation when compared to cells co-cultured with control parental cells over a period of 72 
h. Furthermore, the total AKT in CD40-stimulated cells appeared to be mostly located in a higher 
molecular weight band (Figure 1A), suggesting that most of it becomes phosphorylated. It was also 
noted that the level of total AKT was reduced when it was phosphorylated. Since the p-AKT and total 
AKT were probed on 2 separate membranes, reduction of total AKT is thus likely caused by the 
accelerated proteasomal degradation of p-AKT that serves as a negative feedback mechanism to 
terminate AKT activation [37]. To confirm that the CLL cells had been stimulated via CD40, we 
measured expression of BCL-XL as a surrogate marker of such stimulation [34]. As expected, BCL-XL 
was up-regulated in CLL cells co-cultured with CD154-expressing fibroblasts throughout the 72 h 
incubation period (Figure 1A). The pooled densitometry data analysis showed that the increase in p-
AKT following CD40 stimulation was maximum at 24 h when levels were 2-fold higher compared 
with CLL cells that had been co-cultured with the parental fibroblasts (p<0.05) (Figure 1B). 
To understand how CD40 stimulation might increase AKT phosphorylation, we investigated its effect 
on the expression of PTEN (the major negative regulator of PI3K/AKT [38]). Experiments were 
performed in the presence or absence of interleukin (IL)-4 or IL-21, both of which are produced by T 
cells and enhance and/or modulate the effect of CD40 stimulation [10,39]. As expected, CD40 
stimulation alone produced an increase in p-AKT (Figure 1C). In contrast, levels of PTEN were 
markedly decreased in the CLL cells co-cultured with CD154-expressing fibroblasts when compared 
to that in cells co-cultured with parental fibroblasts (Figure 1C). The analysis of pooled densitometry 
data showed that this decrease in PTEN was also statistically significant at 24 h (Figure 1E). The 
increase in p-AKT and decrease in PTEN following CD40 stimulation were both largely unaffected by 
the addition of IL-4 or IL-21 (Figures 1C-E). Taken together, these findings clearly demonstrate that 
CD40 stimulation induces the activation of AKT and that this activation is associated with, and likely 
caused by, reduced expression of PTEN. 
2. Inhibition of bendamustine-induced cell death by CD40 stimulation is mediated by AKT 
Having shown that AKT is activated by CD40 stimulation in CLL cells, we next sought to establish 
whether activated AKT contributes to the cytoprotective effect of CD40 stimulation against drug-
induced killing in stimulated cells. To this end, we used a novel, selective ATP-competitive inhibitor 
of AKT, AZD5363 [40]. Preliminary experiments showed that the inhibitor potently inhibited AKT 
activity, as measured by de-phosphorylation of GSK3α/β, in CLL cells after incubation for 24 h under 
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standard conditions with an estimated IC50 of 3 µM (Supplementary Figures 1A and B). However, 
AZD5363 at concentrations up to 30 µM did not induce cell death in these cells (Supplementary 
Figures 1C and D). The inhibitor also produced a concentration-dependent reduction of AKT activity 
in CD40-stimulated CLL cells with 10 µM AZD5363 achieving greater than 50% inhibition 
(Supplementary Figures 2A and B). We therefore used AZD5363 at a concentration of 10 µM for 
subsequent experiments. We chose the cytotoxic drug bendamustine owing to its expanding role in 
the treatment of previously untreated and recurrent CLL [41,42]. CLL cells were co-cultured on 
monolayers of control or CD154-expressing fibroblasts in the presence or absence of bendamustine 
with or without the AKT inhibitor, and monitored for the induction of cell death at 24 and 48 h. As 
shown in Figures 2A and B, CLL cells co-cultured with CD154-expressing fibroblasts had a reduced 
spontaneous cell death at both time points when compared with cells co-cultured with control 
fibroblasts. In addition, cell death induced by bendamustine at both 30 and 100 μM was significantly 
reduced in CD40-stimulated CLL cells as compared to cells co-cultured with control fibroblasts at 24 
and 48 h (Figures 2A and B). Importantly, addition of 10 μM AZD5363 not only increased 
spontaneous cell death in cells co-cultured with CD154-expressing fibroblasts, but also restored 
sensitivity of CD40-stimulated CLL cells to bendamustine-induced killing to the levels seen in the CLL 
cells co-cultured with control fibroblasts at both time points (Figures 2A and B). The above results 
clearly indicate that AKT mediates chemoresistance due to CD40 stimulation.  
3. Stimulation of CLL cells via CD40 + IL-4 or IL-21 induces cell growth that is partly dependent 
on AKT 
We next focused our attention on the growth and proliferation of CLL cells given the established role 
of AKT in regulating these processes in other cells. We first examined co-cultured CLL cells for an 
increase in cell size which is known to be one of the functional consequences of CD40 stimulation 
[43]. To do this, we used forward light scatter (FSC) obtained by flow cytometry as an indicator of 
cell size, as described [43]. We first compared the FSC properties of CLL cells co-cultured with 
CD154-expressing versus parental fibroblasts in the presence of IL-4. As expected, a time-dependent 
increase in FSC was observed in CLL cells co-cultured with CD154-expressing fibroblasts, whereas no 
such increase was seen in cells co-cultured with control fibroblasts (Supplementary Figures 3A and 
B). The increase in FSC in CD40-stimulated cells was observed as early as day 1 following co-culture 
with CD154-expressing fibroblasts and continued to increase over the next 3 days (Supplementary 
Figure 3B). Similar experiments were performed with CLL cells stimulated by CD40 + IL-21 (since IL-
21 induces apoptosis in CLL cells cultured in the absence of CD40 stimulation [39], the control for 
this experiment did not include IL-21). As with CD40 + IL-4, a similar time-dependent increase in FSC 
was observed in CD40 + IL-21-stimulated cells, whereas no such increase was observed in CLL cells 
co-cultured with control fibroblasts alone (Supplementary Figures 3C and D). Again, the increase in 
cell size was statistically significant on day 1 following co-culture with CD154-expressing fibroblasts 
and increased further over the next 3 days (Supplementary Figure 3D). 
To determine whether the increased size of CLL cells induced by CD40 stimulation was mediated by 
AKT, co-cultured CLL cells were again treated with the AKT inhibitor AZD5363. As shown in 
Supplementary Figure 3E, AZD5363 significantly reduced the increase in cell size due to stimulation 
by CD154 plus IL-4, although not to the background levels seen in cells co-cultured with control 
fibroblasts. Similar levels of inhibition of cell expansion by AZD5363 were also observed in CLL cells 
co-cultured with CD154-expressing fibroblasts in the presence of IL-21 (Supplementary Figure 3F).  
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To confirm the effects observed with AZD5363, we repeated the experiments using another AKT 
inhibitor: MK-2206. We chose MK-2206 as it inhibits AKT activity by binding to the plextrin-homology 
domain of the enzyme, preventing its translocation to the membrane and subsequent activation 
[44], thus utilising a mode of action different to that of AZD5363. MK-2206 has also been shown to 
induce apoptosis in CLL cells in vitro, with an LC50 of 8 µM after 72 hours incubation under standard 
culture conditions [45]. We therefore used MK-2206 at a concentration of 1, 3 and 10 µM in our 
experiments. Similar to AZD5363, MK-2206 inhibited the CD40 stimulation-induced increase in cell 
size in a concentration-dependent manner in all CLL samples examined (Supplementary Figure 3G). 
Taken together, the above results strongly suggest that increase in size of CLL cells induced by CD40 
stimulation is at least in part mediated by AKT. 
4. CLL cells undergo mitosis following stimulation by CD40 in the presence of IL-4 or IL-21 
We next examined the role of AKT in CLL-cell mitosis. To do this, CLL cells pre-incubated with the 
supravital fluorochrome CFSE were co-cultured with CD154-expressing fibroblasts in the presence of 
recombinant human IL-4 or IL-21. Proliferation was detected as a reduction in fluorescence intensity 
due to CFSE as described previously [39]. CFSE-labelled CLL cells were also co-cultured with parental 
fibroblasts as a negative control. As shown in Figure 3A, CLL-cell proliferation was more rapid, 
pronounced and consistent following stimulation with CD154 + IL-21 as compared with CD154 + IL-4 
(Figure 3A). To establish the identity of the divided cells, aliquots of cells harvested at the indicated 
time points were tested for expression of CD5 and CD19.  As shown in Supplementary Figure 4, most 
of the cells with reduced CFSE fluorescence intensity were shown to be double positive for both CD5 
and CD19, confirming that these divided cells were indeed CLL cells. 
Quantitative analysis of the percentage of divided cells in the time-course experiments confirmed 
that CD154 + IL-21 was more potent than CD154 + IL-4 in inducing CLL-cell mitosis in terms of both 
magnitude and speed (Figure 3B). Thus, CD154 + IL-21 produced a significantly higher percentage of 
divided cells, with a significant difference seen as early as day 5 and persisting for at least 9 days 
(Figure 3B). 
5. AKT contributes to mitosis induced by CD40 + IL-4  
Next, we examined the role of AKT in CLL-cell proliferation induced by CD154 + IL-4. To do this, we 
again used AZD5363 at 10 µM. As shown in Figure 4A, treatment of the stimulated CLL cells with 
AZD5363 significantly inhibited the loss of fluorescence due to CFSE, indicating that AKT contributes 
to mitosis induced by CD154 + IL-4. This was confirmed by quantitative analysis (Figure 4B). 
Importantly, AZD5363 had no effect on the viability of CLL cells stimulated by CD154 + IL-4 (Figure 
4C). This observation indicates that the anti-mitotic effect of AZD5363 was specific and not simply 
the consequence of cytotoxicity. It also suggests that IL-4 can overcome the pro-death effects of AKT 
inhibition in the CD154 co-culture system. 
6. AKT contributes to mitosis induced by CD40 + IL-21 in most but not all cases 
We then investigated the role of AKT in CLL-cell proliferation induced by CD154 + IL-21 using a 
similar approach, but employing a range of concentrations of the inhibitor. In contrast to the results 
obtained with CD154 + IL-4, pooled analysis of eight CLL samples stimulated with CD154 + IL-21 
failed to show any significant changes in the percentage of divided cells as a result of AKT inhibition 
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with AZD5363 (P>0.05). However, analysis of individual patient samples showed that the AKT 
inhibitor reduced the percentage of divided CLL cells in a concentration-dependent manner in six out 
of the eight cases (Figure 5A, blue symbols). AZD5363 at 10 µM concentration has significantly 
reduced the percentage of proliferating CLL cells in these samples at days 5, 6, 7 and 8 (P<0.05, 
Figure 5A). In contrast, AZD5363 failed to inhibit proliferation induced by CD154 + IL-21 in two other 
CLL samples (Figure 5A, red symbols). In the case of sample 3355, the AKT inhibitor further increased 
proliferation induced by CD154 + IL-21. AZD5363 at these concentrations did not induce cell death in 
CLL cells from all patient samples (Figure 5B), indicating that its effect on proliferation was selective 
and not due to cytotoxicity. It also suggests that IL-21 can overcome the pro-death effects of AKT 
inhibition in the CD154 co-culture system. 
To confirm the anti-proliferative effects of AZD5363, the above experiments were repeated using 
MK-2206 at concentrations of 1, 3 and 10 µM. In the six samples where proliferation was inhibited 
by AZD5363, MK-2206 produced a concentration-dependent inhibition of CLL-cell mitosis induced by 
CD154 + IL-21 (Supplementary Figure 5A, blue symbols). MK-2206 at concentrations of 1 and 3 µM 
had no effect on cell viability at these concentrations (Supplementary Figure 5B). Similarly, in the 
two samples where proliferation was not inhibited by AZD5363, MK-2206 at concentrations of 1 and 
3µM did not significantly inhibit CLL-cell mitosis induced by CD154 + IL-21 (Supplementary Figure 5A, 
red symbols). When MK-2206 was used at a concentration of 10 µM, a reduction in the percentage 
of divided cells was observed (Supplementary Figure 5A). However, this corresponded to a reduction 
in viability (Supplementary Figure 5B). MK-2206 at 10 µM reduced the viability particularly in the 
two samples where proliferation was not inhibited by AZD5363 and MK-2206 at 1 and 3 µM 
concentrations, with an average viability of 51% at day 5, 50% at day 6, 24% at day 7 and 23% at day 
8, respectively. This indicates a cytotoxic effect of the inhibitor at this concentration. Taken together, 
the two AKT inhibitors with different modes of action produced similar effects on CLL-cell mitosis 
induced by CD154 + IL-21, both inhibiting proliferation in the same six patient samples but not 
inhibiting such proliferation in the two other samples. 
7. AKT inhibition in CD40 + IL-21-stimulated cells is associated with repression of cyclin A2 and 
CDK1 
In an attempt to identify molecules involved in the anti-proliferative effect of AKT inhibition, the 
same CLL samples were co-cultured with CD154-expressing fibroblasts in the presence of IL-21 with 
or without AZD5363 (10 µM) for 24 h, 48 h and 72 h and analysed by Western blotting for the 
expression of key molecules involved in cell-cycle regulation. The results were compared between 
cases that were responsive or unresponsive to the anti-proliferative effects of AKT inhibition. CLL 
cells co-cultured with the parental fibroblasts were used as a control. First, we compared the 
expression of cyclins (e.g. A2, D2, D3, E1) and negative regulators of cyclin-dependent kinases 
(including p27 and p21).  
In keeping with previous reports [46,47], unstimulated CLL cells expressed higher levels of p27 
(Figure 6A, lane 1). Levels of p27 were reduced following co-culture with parental control fibroblasts 
(Figure 6A lanes 2-4) and decreased further following co-culture with CD154-expressing fibroblasts + 
IL-21 (Figure 6A, lanes 5-7). We also examined the expression of p21 but failed to detect it in 
unstimulated CLL cells (Figure 6A, lanes 1-4), although it was detected at low levels in CLL cells co-
cultured on CD154-expressing fibroblasts (Figure 6A, lanes 5-7). Addition of AZD5363 restored the 
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expression of p27 but had little effect on the expression of p21 (Figure 6A, lanes 8-10). There was no 
difference in the expression of p27 and p21 or in the effect of AZD5363 on this expression between 
CLL samples that were responsive or unresponsive to the anti-proliferative effects of AKT inhibition. 
As expected, unstimulated CLL cells expressed hardly any cyclins (Figure 6A, lane 1). Co-culture with 
control fibroblasts induced the expression of cyclins D2 and D3, but not cyclins A2 and E1 (Figure 6A, 
lanes 2-4). However, cyclins A2 and E1 were upregulated following stimulation by CD154 + IL-21 
(Figure 6A, lanes 5-7). Interestingly, addition of AZD5363 consistently inhibited induction of cyclin 
A2, but not cyclin E1 in all the samples examined (Figure 6A, lanes 8-10). Pooled data analysis 
showed that inhibition of cyclin A2 expression by AZD5363 was statistically significant (Figure 6B). 
There was again no difference in the expression of cyclins or in the effect of AZD5363 on this 
expression between CLL samples that were responsive or unresponsive to the anti-proliferative 
effects of AKT inhibition. 
Next, we compared expression of cyclin-dependent kinases (CDKs) 1, 2 and 4 in these CLL cells. As 
shown in Figure 6C (lane 1), unstimulated CLL cells expressed very little amount of these CDKs. CDK2 
expression was increased in CLL cells co-cultured with parental fibroblasts, but unaffected by CD40 
stimulation (Figure 6B, compare lanes 5-7 to lanes 2-4) or AZD5363 (Figure 6C, lanes 8-10). CDK4 was 
induced in CLL cells following stimulation by CD154 + IL-21 (Figure 6C, lanes 5-7), as was CDK1 
(Figure 6C, lane 7). However, compared to CDK4, induction of CDK1 appeared to be delayed as it was 
only detected on day 3 in all the CLL samples examined (Figure 6C, lane 7). CDK1 induction was 
consistently inhibited by AZD5363 (Figure 6C, lane 10), although pooled data analysis failed to show 
statistical significance (Figure 6D). Again, there was no difference in the expression of CDKs or in the 
effect of AZD5363 on this expression between CLL samples that were responsive or unresponsive to 
the anti-proliferative effects of AKT inhibition. 
In summary, co-culture of CLL cells with control fibroblasts reduced p27 expression and increased 
the expression of cyclin D2, cyclin D3 and CDK2. Stimulation with CD154 + IL-21 further reduced the 
expression of p27 and increased the expression of p21, cyclin A2, cyclin E1, CDK1 and CDK4. 
AZD5363 inhibited some of these effects (p27 repression and induction of p21, cyclin A2, cyclin D2, 
cyclin D3 and CDK1) but not others (induction of cyclin E1, CDK2 and CDK4).  Importantly, no 
differences were observed in the expression of any of these proteins or in the effect of AZD5363 on 
this expression between CLL samples that were responsive or unresponsive to the anti-proliferative 
effects of AKT inhibition. The molecular mechanisms responsible for the variable effect of AKT 
inhibition on CLL-cell proliferation induced by CD154 + IL-21 therefore still remain to be elucidated. 
8. Proliferation of normal B cells induced by CD154 + IL-4 or IL-21 does not involve AKT 
Finally, to investigate whether inhibition of CD154 + IL-4 or IL-21-induced proliferation by the AKT 
inhibitors is selective to CLL cells, we repeated the experiment using normal B cells purified from 
buffy coats by negative selection using a commercially available B cell isolation kit. As shown in 
Figure 7A, normal B cells were readily induced to proliferate on day 3 when co-cultured with CD154-
expressing fibroblasts + IL-4, as indicated by the formation of a sub-peak on the CFSE fluorescence 
histograms (Figure 7A, blue line). In contrast to CLL cells, such proliferation in normal B cells was not 
inhibited by co-incubation with 10 µM AZD5363 (Figure 7A, orange line). This suggests that the anti-
proliferative effect of AZD5363 is relatively selective to CLL cells. Consistent with the above 
observation, normal B cells were also readily induced to proliferate following stimulation by CD154 + 
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IL-21 (Figure 7B, blue line). Quantitative analysis of the data showed that significant amounts of 
divided cells (36 % ± 25.1) were detected by day 4 (Figure 7D, blue dots). By day 5, % of divided cells 
increased to 57.5% (±18.2) (Figure 7D, red dots). The addition of 1 – 10 µM AZD5363 had no effect 
on this proliferation (Figures 7B and D). The same was true of 1 – 10 µM MK-2206 (Figures 7C and 
D). Neither AZD5363 nor MK-2206 at the concentrations used in the study induced significant 
amounts of cell death in stimulated normal B cells (Figure 7E). Collectively, these results suggest that 
AKT inhibition by AZD5363 or MK-2206 does not inhibit the proliferation of normal B cells induced by 
CD154 + IL-21 and that AKT is therefore not required for proliferation of normal B cells in response 
to CD40 stimulation. 
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Discussion 
This study was conducted to determine whether AKT plays a role in CD40 stimulation-mediated cell 
survival, growth and proliferation of CLL cells and, in doing so, further elucidate the role of AKT in 
CLL biology. We confirmed previous reports that CD40 stimulation induces activation of AKT in CLL 
cells [21,35,36]. We also showed that this activation was associated with decreased expression of 
PTEN, a result consistent with a recent report that CD40 stimulation results in a specific induction of 
microRNA-22, a cellular inhibitor of PTEN, which subsequently leads to AKT activation in CLL cells 
[48]. 
To address the extent to which AKT mediates the pro-survival effect of CD40 stimulation, we co-
cultured CLL cells on a monolayer of CD154-expressing fibroblasts and compared their viability to 
that in cells co-cultured with control fibroblasts. Our demonstration that CD40-stimulated CLL cells 
underwent less spontaneous cell death and were more resistant to bendamustine-induced killing 
confirms that CD154 on the surface of the transfected fibroblasts was engaging with CD40 on the 
CLL cells to generate pro-survival signals. Furthermore, our observations that pharmacological 
inhibition of AKT reduced the survival of the stimulated CLL cells and sensitized them to killing by 
bendamustine strongly implicates AKT as an important mediator of CD40-derived pro-survival 
signals.  
We have also shown for the first time that AKT is required for CD40-induced cell growth as measured 
by an increase in the size of stimulated CLL cells. This is not unexpected since AKT is known to 
regulate growth and cell size via mTOR and its downstream targets S6K1 and 4EBP1/eIF4E [49], and 
by stimulating protein synthesis and inhibiting protein degradation [50]. It has also been shown that 
AKT maintains cell size and survival by increasing mTOR-dependent nutrient uptake, which is 
required for protein synthesis [51]. 
Regarding the variation in kinetics of proliferation observed in our co-culture system between CLL 
cells and normal B cells and between different cases of CLL, our results are entirely in agreement 
with in-vivo studies showing that normal B cells proliferate more rapidly (1.5-4.24% per day) [52,53] 
than CLL cells (0.08-1.7% per day) [53,54] and that proliferation kinetics vary widely between 
different cases of CLL [53,55]. Importantly, pharmacological inhibition of AKT inhibited the 
proliferation of CLL cells in most cases irrespective of the rate of mitosis but had no effect on the 
proliferation of normal B cells. This observation suggests that AKT plays a more prominent role in 
signalling proliferation induced by CD40 + IL-4 or IL-21 in CLL cells as compared with B cells.  
Our data suggest that the role of AKT in CLL-cell proliferation induced via CD40 is both stimulus and 
case dependent. The pronounced and consistent inhibitory effect of AKT inhibition on CLL-cell 
proliferation induced by CD154 + IL-4 implies a crucial role for AKT in signalling mitosis in CLL cells 
under such conditions. This is entirely in keeping with a recent report demonstrating a key role of 
the PI3K/AKT pathway in CLL-cell proliferation induced by CD154 + IL-4 [48]. It is also in agreement 
with a previous report implicating AKT as a mediator of proliferation following stimulation of CLL 
cells with CpG-oligodeoxynucleotides [56]. In contrast to results obtained with CD40 + IL-4, when CLL 
cells were stimulated to proliferate by CD154 + IL-21, pharmacological inhibition of AKT reduced 
proliferation in most but not all patient samples indicating an inconsistent role for AKT in signalling 
proliferation under these circumstances. A recent report that the JAK inhibitor (ruxolitinib) almost 
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completely inhibited CLL-cell proliferation induced by CD154 + IL-21 [39], suggests that the JAK-STAT 
pathway may dominate over AKT in transmitting proliferation signals under these circumstances. 
In order to identify the molecules responsible for mediating the differential effect of AKT inhibition 
on proliferation induced by CD40 + IL-21, we compared changes in the expression of cell cycle 
regulatory molecules following stimulation of CLL with CD154 + IL-21 in the presence or absence of 
AKT inhibitors. It has recently been shown that lenalidomide inhibits CLL-cell proliferation induced by 
CD154 + IL-4 + IL-10 in a cereblon/p21-dependent manner but independently of p53 [57]. It is also 
known that levels of p21 protein can be negatively modulated by AKT through direct or indirect 
phosphorylation [24-26]. As a result, CDKs are liberated and allowed to restore their kinase function 
in cell cycle progression. We therefore speculated that the differential effect of AKT inhibition on 
CD40 + IL-21-induced proliferation could be mediated via differential induction of p21. However, we 
were unable to detect p21 expression in unstimulated CLL cells and could only detect it at low levels 
following stimulation with CD154 + IL-21. Importantly, AKT inhibition had little effect on the 
expression of p21 in all the samples examined. Instead, we found that AKT inhibition reduced the 
expression of cyclin A2 and CDK1 consistently in all the samples examined irrespective of whether 
their proliferation was inhibited or not. Therefore, the molecular mechanisms underlying the 
variable effect of AKT inhibition on CLL-cell proliferation induced by CD40 + IL-21 remain to be 
elucidated.  
In summary, we have shown that AKT is an important mediator of CLL-cell survival, growth and 
chemoresistance induced by CD40 stimulation. We also showed that AKT is required for proliferation 
of CLL cells in response to CD154 + IL-4 and contributes to proliferation induced by CD154 + IL-21 in 
CLL cells in most patient samples. From a clinical perspective, the sensitisation of CLL cells to killing 
by bendamustine that was observed when the AKT inhibitor was added to the CD154 co-culture 
system provides a strong rationale for combining AKT inhibitors with chemotherapy-based 
treatment in order to augment cytoreduction at sites of tissue involvement. Furthermore, the anti-
proliferative effect of AKT inhibition suggests that AKT inhibitors might delay re-growth of the 
residual leukemic clone in most patients as post-induction maintenance therapy.  
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Methods and materials 
CLL cell and normal B cell preparation. Peripheral blood samples from CLL patients were obtained 
with informed consent and the approval of the Liverpool Research and Ethics Committee. The 
clinical details of the patients included for this study are given in Table 1.  CLL cells were isolated by 
centrifugation of blood over Lymphoprep (Axis-Shield PoC AS, Oslo, Norway) and stored in a -150°C 
freezer prior to use. Normal B cells were purified by negative selection using a B cell isolation kit 
(Miltenyi Biotech, Bisley, UK) from Buffy coats obtained from the National Blood Service (Liverpool, 
UK). B-cell purity was determined by CD19 staining and flow cytometry. 
Chemicals, antibodies and other reagents. AKT inhibitor AZD5363 was provided by AstraZeneca 
(London, UK). Another AKT inhibitor MK-2206 was purchased from Selleck Chemical (via Stratech 
Scientific Ltd., Suffolk, UK). Bendamustine hydrochloride hydrate was obtained from Sigma-Aldrich 
(Gillingham, UK). Rabbit monoclonal antibodies against phospho-AKT (Ser473) (clone D9E), phospho-
GSK-3α/β (Ser21/9) (clone D17D2), CDK2 (clone 78B2), CDK4 (clone D9G3E), Cyclin D2 (clone D52F9), 
p21 (DCS60) and p27 (D69C12), and mouse monoclonal antibodies to CDK1 (clone POH1), Cyclin A2 
(clone BF683), Cyclin D3 (clone DCS22), Cyclin E1 (clone HE12), and rabbit polyclonal antibodies to 
total AKT, BCL-XL and PTEN were all obtained from Cell Signalling Technology (via New England 
Biolabs, Herts, UK). Mouse monoclonal antibody to GSK3α/β (clone 21A) was obtained from Life 
Technologies (Paisley, UK). Mouse monoclonal antibody to β-actin (clone AC-74) was from Sigma-
Aldrich. Secondary antibodies, goat anti-mouse IgG-HRP and goat anti-rabbit IgG-HRP were from 
Santa Cruz Biotechnology (Insight Biotechnology, Middlesex, UK). Other chemicals, unless otherwise 
stated, were all obtained from Sigma-Aldrich. 
Co-culture of CLL cells. Stably transfected mouse fibroblasts expressing human CD154 and control 
parental fibroblasts (both kindly provided by Professor Gerald Cohen at University of Liverpool) were 
maintained as described [34]. After thawing, CLL cells were maintained in RPMI 1640 medium 
supplemented with 10 % heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/ml 
penicillin, and 100 μg/ml streptomycin (Life Technologies). For CD40 stimulation, CLL cells were 
seeded on an adherent monolayer of CD154-expressing or control fibroblasts at a ratio of 10:1 and 
incubated at 37°C for an appropriate period of time, as described [34]. To determine the effects of 
bendamustine and AZD5363 on cell survival following CD40 stimulation, CLL cells were co-cultured 
for 24h or 48h with the CD154-expressing or parental fibroblasts in the presence or absence of the 
above drugs before harvesting. To induce proliferation and determine the effect of AKT inhibition on 
proliferation, CLL cells were co-cultured with CD154-expressing fibroblasts in the presence of 
recombinant human interleukin-4 (IL-4, R&D Systems, Minneapolis, MN ) or IL-21 (Life Technologies), 
with or without the AKT inhibitors for up to ten days.  
Analysis of cell death by flow cytometry.  CLL cells were co-cultured with CD154-expressing or 
control fibroblasts in the presence or absence of cytotoxic agents at the indicated concentrations. At 
the end of the incubation period, co-cultured CLL cells were harvested as described [34] and their 
viability was determined by propidium iodide exclusion and flow cytometry as previously described 
[58]. Aliquots of cells from the same experiment were analysed by Western blotting for the 
expression of specific proteins. 
Analysis of proliferation by flow cytometry. CLL cells were first incubated at 37°C for 10 minutes in 
complete RPMI 1640 medium containing 0.5 µM carboxyfluorescein diacetate succinimidyl ester dye 
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(CFSE, Molecular Probes®, Life Technologies) and then washed with fresh medium to remove excess 
dye.  Cells were then incubated for a further 20 minutes at 37°C and washed again before being  re-
suspended in fresh medium containing recombinant human IL-4 (at 10 ng/ml) or IL-21 (at 12.5 
ng/ml) and seeded onto an adherent monolayer of CD154-expressing fibroblasts described above. At 
the end of indicated incubation periods, cells were gently removed from the respective monolayers 
and analysed by flow cytometry using excitation and emission wavelengths of 488 nm and 517 nm, 
respectively, according to manufacturer’s protocol. FlowJo software (7.6.5 version) (FlowJo, Ashland, 
OR) was used to analyse proliferation data of CFSE-labelled CLL cells and calculate the percentage of 
divided cells, as described [39]. 
Western blotting. At the end of the incubation, co-cultured CLL cells were harvested and washed 
once in ice-cold phosphate-buffered saline (PBS) and lysed using 100 μl of RIPA buffer (50 mM 
Tris/HCl (pH 7.6), 1% (w/v) Triton-X100, 150 mM NaCl, 0.1% (w/v) sodium dodecyl sulfate (SDS), 
0.5% (w/v) sodium deoxycholate, and protease and phosphatase inhibitor cocktails (Sigma-Aldrich). 
Cell lysates were further sonicated using Diagenode Bioruptor® (Diagenode Inc, Liège, Belgium). 
Sonicated cell lysates were cleared of debris by centrifuging at 10,000g for 10 min at 4°C and protein 
concentration determined using RC DC Protein Assay Reagents Kit (BioRad laboratories, Herts, UK). 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting were performed essentially 
as described [31]. Briefly, cellular proteins were separated on a SDS-polyacrylamide gel and 
transferred to Immobilon-P polyvinilidene difluoride membranes (Millipore Corporation, Bedford, 
MA) which were then probed with the appropriate primary antibodies. Immunoreactivity was 
detected using the relevant HRP-labelled secondary antibodies (Santa Cruz Biotechnology), which 
were visualized on an Image Reader LAS-1000 (Fujifilm, Tokyo, Japan) using an enhanced 
chemiluminescence kit (Millipore). For quantification of the signals, the images were further 
analysed on the same instrument using 2D Densitometry Aida Image Analyzer software (Fujifilm). 
Statistical analysis. Where appropriate, a two-tailed, paired t-test was performed to determine the 
statistical significance of the difference between the two groups of data. 
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Table 1. Clinical characteristics of the CLL samples used 
 
Sample 
number 
Sex Age at 
diagnosis 
Stage 
(Binet) 
WBC 
(109/l) 
IGHV 
status¶ 
Chromosomal 
abnormalities 
Prior 
therapy* 
#1958 f 65 A 215 M 13q- Y 
#2064 m 46 C 120 UM Tri12 Y 
#2096 m 65 A 60 M 17p- & 13q- N 
#2103 m 56 A 125 UM 17p- & 13q- N 
#2263 m 65 B 366 UM 11q- & 13q- Y 
#2521 f 79 B 74 M Tri12 Y 
#2729 m 66 A 37 M normal N 
#2804 F nd# A 39.7 M nd nd 
#2814 m 72 A 196 UM normal N 
#2996 m nd nd 169.2 M 13q- nd 
#3033 m 66 A 41 M normal N 
#3058 m 69 B 51 UM normal N 
#3091 m nd nd 41.7 UM 11q- nd 
#3106 m 66 C 115 UM 11q- & 13q- nd 
#3129 m nd nd 31.8 UM nd nd 
#3308 m 66 C nd UM nd nd 
#3353 f 75 A 72 M nd nd 
#3355 m 73 B 130 M 13q- nd 
#3365 f nd C 253 nd 13q- nd 
#3379 m 67 B 228.5 UM 17p- Y 
 
¶ IGHV status refers to somatic mutation in IGHV gene of CLL cells as compared with the gene 
sequence of the nearest germ-line using 2% as a cut-off. M=mutated; UM=un-mutated. 
*Prior therapy consisted of various combinations of glucocorticoid, chlorambucil, fludarabine, or 
fludarabine plus cyclophosphamide. 
# nd: not done/unknown 
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Figure legends 
Figure 1. CD40 stimulation-induced AKT activation is associated with decreased expression of PTEN. 
(A) CLL cells were cultured on a monolayer of parental control or CD154-expressing fibroblasts for 
24, 48 and 72 h. At the indicated time points, CLL cells were harvested and analysed for the levels of 
p-AKT (serine 473) and total AKT by Western blotting. BCL-XL was probed as a marker for CD40 
stimulation. β-actin was used as a loading control for densitometric analysis. One representative blot 
from 3 CLL samples examined is shown. (B) shows a pooled data analysis of the effect of CD40 
stimulation on levels of p-AKT in co-cultured CLL cells. In this and subsequent figures, each bar 
represents the mean ± SD, unless otherwise stated. (C) CLL cells were co-cultured for 24 and 48 h as 
in (A) but in the presence or absence of recombinant human IL-4 (10 ng/ml) or IL-21 (12.5 ng/ml). 
CLL cells were then harvested and analysed for levels of p-AKT (serine 473) and PTEN by Western 
blotting. One representative blot from 4 CLL samples examined is shown.  (D) shows a pooled data 
analysis of the effect of CD40 stimulation on levels of p-AKT in co-cultured CLL cells as in (C). (E) 
shows a pooled data analysis of the effect of CD40 stimulation on levels of PTEN in co-cultured CLL 
cells as in (C). 
Figure 2. AKT is required for CD40 stimulation-mediated survival and inhibition of bendamustine-
induced cell death. CLL cells were cultured on a monolayer of control or CD154-expressing 
fibroblasts in the presence or absence of bendamustine at the indicated concentration with or 
without AZD5363 (10 μM) for 24 h (A) and 48 h (B). Co-cultured CLL cells were then harvested at the 
indicated time points and cell death was determined by PI inclusion on flow cytometry as described 
in Method. Each data set represents mean ± SD from 6 independent experiments using CLL cells 
from 4 different patients. Also actual data from individual CLL samples are shown in filled dot. 
Figure 3. Stimulation by CD154 + IL-21 is more potent than that of CD154 + IL-4 in inducing 
proliferation of CLL cells in vitro. (A) CFSE labelled CLL cells were co-cultured with CD154-expressing 
fibroblasts in the presence of recombinant human IL-4 (10 ng/ml) or IL-21 (12.5 ng/ml) over a period 
of up to ten days. CFSE labelled CLL cells co-cultured with parental fibroblasts were used as a 
negative control. At the indicated time points, co-cultured CLL cells were harvested and proliferation 
was measured by reduction of CFSE fluorescence intensity on flow cytometry as described in 
Method. Three representative CFSE histograms from the time-course experiments using primary CLL 
cells from 5 different samples are shown. (B) Pooled data analysis of the divided cell population 
among CLL cells co-cultured as in (A) shows that stimulation of CD40 + IL-21 induced significantly 
higher percentage of divided cells than that of CD40 + IL-4. Percentage of divided cells was 
calculated using FlowJo software as described in Method. 
Figure 4. AKT is required for proliferation induced by CD154 + IL-4. (A) CFSE labelled CLL cells were 
co-cultured with CD154-expressing fibroblasts in the presence of recombinant human IL-4 (10 ng/ml) 
in the presence or absence of AKT inhibitor AZD5363 (10 µM) over a period of 7 days. CFSE labelled 
CLL cells co-cultured with parental control fibroblasts were used as a negative control. At the 
indicated time points, co-cultured CLL cells were harvested and measured for reduction of CFSE 
fluorescence intensity by flow cytometry as in Figure 3A. Representative CFSE histograms of co-
cultured CLL cells between 4 and 7 days from one of the five patient samples are shown. (B) Pooled 
data analysis of % divided cells among co-cultured CLL cells shows that addition of AZD5363 (10 µM) 
significantly reduced % divided cells in CD40 + IL-4-stimulated CLL cells. (C) Viability of co-cultured 
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CLL cells as in (B) was determined by PI exclusion/flow cytometry method as described in Method. 
Pooled data analysis shows that 10 µM AZD5363 had no effect on cell viability of co-cultured cells.  
Figure 5. AKT is only required for CD154 + IL-21-induced proliferation in CLL cells from most, but not 
all patients. (A) CFSE labelled CLL cells were co-cultured with CD154-expressing fibroblasts in the 
presence of recombinant human IL-21 (12.5 ng/ml) in the presence or absence of AZD5363 at the 
indicated concentrations over a period of 8 days. At the indicated time points, co-cultured CLL cells 
from eight individual patient samples were harvested and measured for reduction of CFSE 
fluorescence intensity by flow cytometry as in Figure 3A. Percentage of divided cells was calculated 
as in Figure 3B. Data from samples that were responsive to inhibition of proliferation by AZD5363 as 
indicated by blue symbols is represented by mean ± SD from independent experiments using CLL 
cells from six different patients. Data from samples where proliferation was not inhibited by 
AZD5363 is indicated with red symbols. (B) Viability of co-cultured CLL cells as in (A) was determined 
as in Figure 4C. Pooled data analysis shows that AZD5363 at the indicated concentrations had no 
effect on cell viability of co-cultured cells as described in (A).  
Figure 6. AKT is required for the induction of cyclin A2 and CDK1 by CD40 + IL-21 stimulation. (A) CLL 
cells were cultured on a monolayer of control or CD154-expressing fibroblasts in the presence of 
recombinant human IL-21 (12.5 ng/ml) over a period of 3 days with or without 10 µM AZD5363. At 
the indicated time points, CLL cells were harvested and analysed for levels of cyclins A2, D2, D3 and 
E1, and p27 and p21 by Western blotting. β-actin was used as a loading control for densitometric 
analysis. One representative set of blots from the three of the 5 CLL samples described in Figure 5A 
is shown. (B) shows a pooled data analysis of the effect of AZD5363 on level of cyclin A2 in the co-
cultured CLL cells as in (A). (C) CLL cells co-cultured under conditions as in (A) were harvested and 
analysed for levels of CDKs 1, 2 and 4 by Western blotting. β-actin was used as a loading control for 
densitometric analysis. One representative set of blots from the three of the 5 CLL samples 
described in Figure 5A is shown. (D) shows a pooled data analysis of the effect of AZD5363 on level 
of CDK1 in the co-cultured CLL cells as in (C). 
Figure 7. CD40 stimulation-induced proliferation in normal B cells does not require AKT. (A) CFSE 
labelled normal B cells were co-cultured with CD154-expressing fibroblasts in the presence of 
recombinant human IL-4 (10 ng/ml) over a period of six days with or without AZD5363 (10 µM). CFSE 
labelled normal B cells co-cultured with parental fibroblasts plus IL-4 were used as a negative 
control. At the indicated time points, co-cultured B cells were harvested and proliferation was 
measured as in Figure 3A. One set of representative CFSE histograms from the time-course 
experiments using three individual normal B cell samples is shown. (B) CFSE labelled normal B cells 
were co-cultured with CD154-expressing fibroblasts in the presence of recombinant human IL-21 
(12.5 ng/ml) over a period of five days with or without AZD5363 at the indicated concentrations. At 
the indicated time points, co-cultured B cells were harvested and proliferation was measured as in 
(A). One set of representative CFSE histograms from three different normal B cell samples examined 
is shown. (C) CFSE labelled normal B cells were co-cultured with CD154-expressing fibroblasts in the 
presence of recombinant human IL-21 (12.5 ng/ml) over a period of five days with or without MK-
2206 at the indicated concentrations. At the indicated time points, co-cultured B cells were 
harvested and proliferation was measured as in (A). One set of representative CFSE histograms from 
three different normal B cell samples examined is shown. (D) Pooled data analysis shows that 
neither AZD5363 nor MK-2206 at the indicated concentrations inhibited CD154 + IL-21-induced 
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proliferation in normal B cells. (E) Pooled data analysis on the viability of the co-cultured normal B 
cells as described in (D) shows that neither AZD5363 nor MK-2206 at the indicated concentrations 
adversely affected the viability of the co-cultured normal B cells. 







